Subjects who have a ≥50% worsening of symptoms on the ADHD-RS-IV at Visit 14 (compared to Visit 13, one week into the Double-Blind Phase) and a CGI-I of "much worse" or "very much worse" compared to Visit 13 will be eligible to discontinue the Double-Blind Phase and enter the Open-Label Extension Study at the investigator's discretion, after completing end of study (Visit 15) procedures.